Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
about
Recent progress in pancreatic cancerPancreatic Cancer GeneticsInherited pancreatic cancer syndromesHigh risk of tobacco-related cancers in CDKN2A mutation-positive melanoma familiesSwitching off malignant mesothelioma: exploiting the hypoxic microenvironmentGenetic predisposition to pancreatic cancer.High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screeningIncreased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.Rare presentations of primary melanoma and special populations: a systematic review.Molecular characterization of melanoma cases in Denmark suspected of genetic predispositionBRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE studyRisk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriersPreferences Regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank.Return of Genetic Research Results to Participants and Families: IRB Perspectives and RolesACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromesRisk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) AnalysisWhole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic CancerPrevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer PatientsMIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors.Genomic sequencing of key genes in mouse pancreatic cancer cells.Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.Pancreatic cancer genomes: toward molecular subtyping and novel approaches to diagnosis and therapy.Clinical applications of melanoma genetics.Metabolomics in pancreatic cancer biomarkers research.Team work and cytopathology molecular diagnosis of solid pancreatic lesions.Genetics of pancreatic cancer and implications for therapy.CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An OverviewGermline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging ConceptsFamilial pancreatic cancerNovel nano-drug combination therapeutic regimen demonstrates significant efficacy in the transgenic mouse model of pancreatic ductal adenocarcinoma
P2860
Q24626346-B0AE6570-08B5-49D0-8CC0-4B600C754FB9Q26765235-8078B2EA-8742-49AF-B12B-B2AA1E605185Q26853530-D2E639DF-623D-4C89-B00A-D29EBC5BC0ADQ28242124-C1605FBD-F48A-45BD-B8EE-13AAE66C35DFQ29248727-F796C409-2866-478A-9F82-A6D120216BE0Q34067868-F1987E0A-C639-496C-AFEE-F9C8C4CAD77DQ34452269-0560247B-82CC-4217-85B5-AB7742957950Q34602917-4E6EA009-7C16-48E0-B20D-3A2CCE413DC5Q35147046-3B7FC39B-D715-434F-AB77-64AE6FA0F537Q35213835-7AE0CF2D-6658-4256-9680-F9519FCBE513Q35630278-EB0BA834-F8F7-4E21-BD0E-5AD18B3220D0Q36047747-0A1B513B-D9C4-4991-8CED-8E85ABA61296Q36197062-2DA6F1C8-3E10-48D0-B34C-0A8C57621550Q36198371-DAC28507-E8CA-4833-A6F5-CED4025F5F1CQ36416282-63797E8D-91C3-4175-9CD4-5EDDD7FB536BQ36456106-CC40B29A-6D3F-4BEF-92D2-4B89D3E68604Q36553872-C956D99D-ED9B-4B1C-9099-38AB0DA1CB71Q36581642-74E601B0-0F79-452F-BB70-6CAFCF1EC6C4Q36588574-20C594DA-2DF3-4A0D-8138-0B8C250C8454Q37237804-0AE79172-7BC7-4A80-92AA-A4A9D8703344Q38031421-42E47223-C153-44DF-8F93-B8C6D6F9A675Q38113752-38ECF06A-B069-44C9-B77A-DA2A628A5419Q38197938-CB165592-08E8-43D9-A8E8-45C117A45FE6Q38997162-099F428B-8A28-4903-9661-9C67319C6395Q39132122-DE1ABD95-1311-4E1E-8A49-BB17609A64A8Q49606173-F3538E90-63DE-44F5-B6A6-8E5F74581E38Q52655109-F8932F26-292F-4DC2-9E4F-C254629C1E11Q57091632-80966E86-9EFD-4459-B818-616499D13009Q57165768-5F80E726-42F9-4498-8868-7168D1AA4F9EQ57643835-6507768B-5A08-41B6-8436-1BAAE331FA56Q58790015-8A49A325-174D-40B8-A6D4-4978A49C4413
P2860
Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@ast
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@en
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@nl
type
label
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@ast
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@en
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@nl
prefLabel
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@ast
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@en
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@nl
P2093
P2860
P356
P1476
Prevalence of CDKN2A mutations ...... ations for genetic counseling.
@en
P2093
Eric D Wieben
Gloria M Petersen
Hugues Sicotte
Kari G Rabe
Katrina S Pedersen
Robert R McWilliams
Yanhong Wu
P2860
P2888
P304
P356
10.1038/EJHG.2010.198
P577
2010-12-08T00:00:00Z
P5875
P6179
1018225761